Global Health to meet investors on June 17-18, 2026
Global Health Limited has scheduled meetings with analysts and institutional investors on June 17 and 18, 2026. The management will engage with JP Morgan and IIFL Capital in Noida and London respectively. No unpublished price sensitive information will be disclosed during these sessions.

*this image is generated using AI for illustrative purposes only.
Global Health Limited has scheduled meetings with analysts and institutional investors on June 17 and 18, 2026, to discuss business performance and strategy. The management will engage with JP Morgan and IIFL Capital during these sessions, which will be conducted in person in Noida and London respectively. No unpublished price sensitive information will be disclosed during the meetings, adhering to regulatory compliance standards.
Meeting Schedule
The interactions are organized as per Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule includes a group meeting and a one-on-one session, both subject to change due to unforeseen circumstances involving the analysts, investors, or the company.
| Name | Date of Meeting | Type of Meeting | Place of Meeting | Mode of Meeting |
|---|---|---|---|---|
| JP Morgan | June 17, 2026 | Group Meeting | Noida | In Person |
| IIFL Capital | June 18, 2026 | One to One | London | In Person |
Regulatory Compliance
The intimation was submitted to the stock exchanges by Rahul Ranjan, Company Secretary & Compliance Officer of Global Health Limited. The filing explicitly states that the purpose of these meetings is investor interaction and does not involve the sharing of material non-public information. The company has requested the exchanges to take the schedule on record.
Historical Stock Returns for Global Health
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.23% | -1.62% | +2.25% | +5.86% | +2.98% | +193.74% |
What strategic priorities is Global Health Limited likely to emphasize during these investor meetings?
How might the outcomes of these sessions influence investor sentiment toward Global Health Limited?
What potential market reactions could arise from the discussions with JP Morgan and IIFL Capital?


































